DNA methylation and miR‐92a‐3p‐mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway

Author:

Zhu Sixian1,Xu Huiting2,Chen Runzhi2,Shen Qian1,Yang Dongmei2,Peng Hui1,Tong Jin3,Fu Qiang1ORCID

Affiliation:

1. Department of Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

2. Department of Abdominal Oncology, Hubei Cancer Hospital Wuhan China

3. Department of PICC, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

Abstract

AbstractPancreatic cancer (PAAD) is a highly malignant tumour characterized of high mortality and poor prognosis. Huntingtin‐interacting protein 1‐related (HIP1R) has been recognized as a tumour suppressor in gastric cancer, while its biological function in PAAD remains to be elucidated. In this study, we reported the downregulation of HIP1R in PAAD tissues and cell lines, and the overexpression of HIP1R suppressed the proliferation, migration and invasion of PAAD cells, while silencing HIP1R showed the opposite effects. DNA methylation analysis revealed that the promoter region of HIP1R was heavily methylated in PAAD cell lines when compared to the normal pancreatic duct epithelial cells. A DNA methylation inhibitor 5‐AZA increased the expression of HIP1R in PAAD cells. 5‐AZA treatment also inhibited the proliferation, migration and invasion, and induced apoptosis in PAAD cell lines, which could be attenuated by HIP1R silencing. We further demonstrated that HIP1R was negatively regulated by miR‐92a‐3p, which modulates the malignant phenotype of PAAD cells in vitro and the tumorigenesis in vivo. The miR‐92a‐3p/HIP1R axis could regulate PI3K/AKT pathway in PAAD cells. Taken together, our data suggest that targeting DNA methylation and miR‐92a‐3p‐mediated repression of HIP1R could serve as novel therapeutic strategies for PAAD treatment.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3